BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.68 USD
-0.02 (-2.30%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $0.67 -0.01 (-1.33%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Brokerage Reports
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 61 - 80 ( 110 total )
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clear Clinical Progress; Data Catalysts Imminent; 1Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Phase 2 Prostate Cancer Program Initiated; Catalysts Abound; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Progress Unimpeded Thus Far; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Pivotal Phase 3 Program Enrollment Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Pivotal Phase 3 Program Enrollment Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results; SERENITY and TRANQUILITY Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline in a Single Product Story Materializing; Raising PT to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RELEASE Trial Authorization Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Phase 1b/2 Trial Starts Enrollment; Reiterate Buy; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SERENITY Pivotal Program Initiates Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Clinical Assessment Expansion Into Multiple Solid Tumor Types; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SERENITY Pivotal Program Gets FDA Green Light; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal BXCL501 Program Starting Soon; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Prostate Cancer Foundation Scientific Retreat Takeaways; Solid Financial Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R